Expertise in
11
conditions

Dr. Kent F. Hoskins

Oncology
OSF Saint Anthony Medical Center
5666 E State St, 
Rockford, IL 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Expertise in
11
conditions
OSF Saint Anthony Medical Center
5666 E State St, 
Rockford, IL 

Overview

Kent Hoskins is an Oncologist practicing medicine in Rockford, Illinois.

Dr. Hoskins is highly rated in 11 conditions, according to our data. His clinical expertise encompasses Breast Cancer, Paget Disease of the Breast, Inflammatory Breast Cancer, Familial Colorectal Cancer, and Salpingo-Oophorectomy.

He is actively involved in clinical research, co-authoring 68 peer reviewed articles and participating in 13 clinical trials.

Specialties

Oncology

Licenses

Internal Medicine in IL

Hospital Affiliations

University Of Illinois Hospital And Clinics

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Celtic
  • HMO
  • INSURANCE PLAN
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Provider Partners Health Plan
  • MEDICARE SNP
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Zing Health
  • MEDICARE MAPD
  • MEDICARE SNP
View 6 Less Insurance Carriers -

Locations

OSF Saint Anthony Medical Center
5666 E State St, Rockford, IL 61108

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

Prospective Observational Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
Prospective Observational Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
Enrollment Status: Recruiting
Publish Date: October 08, 2025
Intervention Type: Other, Drug
Study Drug: Carvedilol
Study Phase: Phase 3
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy
Study Phase: Phase 3
A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer With Either Phosphoinositide-3-kinase Catalytic Subunit Alpha (PIK3CA) Mutation or Phosphatase and Tensin Homolog Protein (PTEN) Loss Without PIK3CA Mutation
A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer With Either Phosphoinositide-3-kinase Catalytic Subunit Alpha (PIK3CA) Mutation or Phosphatase and Tensin Homolog Protein (PTEN) Loss Without PIK3CA Mutation
Enrollment Status: Terminated
Publish Date: July 14, 2026
Intervention Type: Drug
Study Drugs: alpelisib, nab-paclitaxel
Study Phase: Phase 3
A Phase IIR/III Trial of Standard of Care Therapy With or Without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
A Phase IIR/III Trial of Standard of Care Therapy With or Without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
Enrollment Status: Completed
Publish Date: July 10, 2026
Intervention Type: Radiation, Procedure
Study Phase: Phase 2/Phase 3
TAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
TAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 01, 2026
Intervention Type: Radiation, Other
Study Phase: Phase 3
ALTernate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant TrEatment (ALTERNATE) in Postmenopausal Women: A Phase III Study
ALTernate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant TrEatment (ALTERNATE) in Postmenopausal Women: A Phase III Study
Enrollment Status: Active_not_recruiting
Publish Date: June 05, 2026
Intervention Type: Drug
Study Drugs: Fulvestrant, Anastrozole
Study Phase: Phase 3
RT CHARM: Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation With Breast Reconstruction
RT CHARM: Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation With Breast Reconstruction
Enrollment Status: Active_not_recruiting
Publish Date: February 24, 2026
Intervention Type: Other, Radiation
Study Phase: Phase 3
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Drug
Study Drugs: Palbociclib, Trastuzumab, Pertuzumab, Letrozole, Anastrozole, Exemestane, Fulvestrant
Study Phase: Phase 3
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
A Phase I/II, Single Arm, Non-randomized Study of Ribociclib (LEE011), a CDK 4/6 Inhibitor, in Combination With Bicalutamide, an Androgen Receptor (AR) Inhibitor, in Advanced AR+ Triple-negative Breast Cancer: Big Ten Cancer Research Consortium BRE15-024
A Phase I/II, Single Arm, Non-randomized Study of Ribociclib (LEE011), a CDK 4/6 Inhibitor, in Combination With Bicalutamide, an Androgen Receptor (AR) Inhibitor, in Advanced AR+ Triple-negative Breast Cancer: Big Ten Cancer Research Consortium BRE15-024
Enrollment Status: Active_not_recruiting
Publish Date: January 02, 2026
Intervention Type: Drug
Study Drugs: bicalutamide, ribociclib
Study Phase: Phase 1/Phase 2
View 9 Less Clinical Trials

68 Total Publications

Breast Cancer Incidence in Asian American, Native Hawaiian, and Pacific Islander Populations.
Breast Cancer Incidence in Asian American, Native Hawaiian, and Pacific Islander Populations.
Journal: JAMA network open
Published: June 30, 2026
Similar Doctors
Expertise in
20
conditions
Expertise in
20
conditions
Referral may be required

CDH Cancer Center

4405 Weaver Pkwy, 
Warrenville, IL 
 (54.1 miles away)
630-352-5450
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Sean Grimm is an Oncologist practicing medicine in Warrenville, Illinois. Dr. Grimm is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Glioma, Astrocytoma, Glioblastoma, and Brain Tumor. Dr. Grimm is currently accepting new patients in some locations.

Expertise in
12
conditions
Expertise in
12
conditions
Referral may be required

Mercyhealth Cancer Institute

8201 E Riverside Blvd, 
Rockford, IL 
 (4.3 miles away)
815-971-6188
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Mayur Narkhede is an Oncologist practicing medicine in Rockford, Illinois. Dr. Narkhede is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Chronic B-Cell Leukemia (CBCL), B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), and Bone Marrow Aspiration. Dr. Narkhede is currently accepting new patients.

Expertise in
10
conditions
Expertise in
10
conditions
Referral may be required

UW Health|Carbone Cancer Center Medical Oncology Clinic

600 Highland Ave, 
Madison, WI 
 (59.7 miles away)
608-915-0100
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Dustin Deming, MD, is a UW Health medical oncologist with a clinical emphasis on gastrointestinal cancers, including colon, rectal, anal, esophageal, liver and pancreatic cancers. He is also a professor at the University of Wisconsin School of Medicine and Public Health in the Department of Medicine, Division of Hematology, Medical Oncology and Palliative Care. Dr. Deming is known for his commitment to delivering evidence‑based, compassionate care to patients facing complex cancer diagnoses.Dr. Deming’s research program focuses on developing improved treatments for specific subtypes of colon cancer and other gastrointestinal malignancies. His work centers on understanding how tumor‑specific genetic mutations influence treatment response, with the goal of creating personalized therapy regimens for individual patients. By using advanced animal models, his research helps bridge the gap between laboratory discoveries and clinical application.In addition to his translational research, Dr. Deming’s laboratory has developed innovative three‑dimensional cell culture techniques to advance clinical cancer research. He also leads efforts to identify new and improved biomarkers to better predict disease behavior and treatment outcomes. Through his combined roles as a clinician, researcher, and educator, Dr. Deming contributes to advancing precision oncology and improving care for patients with gastrointestinal cancers. Dr. Deming is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Colorectal Cancer, PIK3CA-Related Overgrowth Spectrum, Familial Colorectal Cancer, Anal Cancer, and Liver Embolization. Dr. Deming is board certified in Internal Medicine and Medical Oncology. Dr. Deming is currently accepting new patients.

Frequently Asked Questions about Dr. Kent F. Hoskins

How do I make an appointment with Dr. Kent F. Hoskins?

You can book an appointment with Dr. Kent F. Hoskins by calling their office at 815-226-2000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Kent F. Hoskins a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Kent F. Hoskins is classified as an Elite expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Kent F. Hoskins specialize in?

While Dr. Kent F. Hoskins is a Oncology, they have specific expertise in Breast Cancer, Paget Disease of the Breast, and Inflammatory Breast Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Kent F. Hoskins participate in research or clinical trials?

Yes. Dr. Kent F. Hoskins has published 68 articles and abstracts on conditions like Breast Cancer. You can view a list of Dr. Kent F. Hoskins's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Kent F. Hoskins accept my insurance?

Dr. Kent F. Hoskins accepts most major insurance plans, including Aetna and Celtic. We recommend calling the office directly at 815-226-2000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hoskins's expertise for a condition
ConditionClose
View All 9 Advanced Conditions
View All 39 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile